Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eventide Healthcare & Life Sciences Fund Class A Shares (ETAHX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.


1 month+14.08% 3 years--
3 months+10.30% 5 years--
1 year+32.48% Since inception+32.61%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return--+20.66%
Expense ratio1.57%1.39%
Risk 5 year sharpe ratio--1.42
Net assets$344.0M$3.8B
Average market cap$2.0B$35.0B
Average P/E--24.4
Portfolio turnover26%26%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 2 Years
Minimal initial investment$1,000.00
Minimum IRA investment$1,000.00


U.S. stock79.46%
International stock3.55%
Fixed income1.81%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
BLUE bluebird bio Inc4.13%
RARE Ultragenyx Pharmaceutical Inc2.85%
VCYT Veracyte Inc2.77%
DYAX Dyax Corp2.66%
NBIX Neurocrine Biosciences Inc2.40%
BMRN Biomarin Pharmaceutical Inc2.35%
FPRX Five Prime Therapeutics Inc2.25%
TTPH Tetraphase Pharmaceuticals Inc2.19%
COLL Collegium Pharmaceutical Inc2.15%